ABBOTT LABORATORIES

ABT 10-Q · Q2 2025
API behind this page

ABT Q2 2025 request

Playground key active
Request URL /api/financials?ticker=ABT&year=2025&quarter=2
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q2 2025 Q2 2024 YoY
Revenue 11,142 10,377 +7.4%
Show Product Lines breakouts
COVID-19 Testing · Diagnostics 55 102 -46.1%
Show Business Segments breakouts
Diagnostics · Core Laboratory 1,358 1,329 +2.2%
Diagnostics · Molecular 123 127 -3.1%
Diagnostics · Non Us 1,362 1,383 -1.5%
Diagnostics · Non Us 1,007 1,002 +0.5%
Diagnostics · Non Us 88 94 -6.4%
Diagnostics · Non Us 44 49 -10.2%
Diagnostics · Non Us 223 238 -6.3%
Diagnostics · Operating Segments 2,173 2,195 -1.0%
Diagnostics · Point of Care 148 156 -5.1%
Diagnostics · Rapid Diagnostics 544 583 -6.7%
Diagnostics · US 811 812 -0.1%
Diagnostics · US 351 327 +7.3%
Diagnostics · US 35 33 +6.1%
Diagnostics · US 104 107 -2.8%
Diagnostics · US 321 345 -7.0%
Established Pharmaceuticals · Key Emerging Markets 1,059 988 +7.2%
Established Pharmaceuticals · Non Us 1,383 1,294 +6.9%
Established Pharmaceuticals · Non Us 1,059 988 +7.2%
Established Pharmaceuticals · Non Us 324 306 +5.9%
Established Pharmaceuticals · Operating Segments 1,383 1,294 +6.9%
Established Pharmaceuticals · Other 324 306 +5.9%
Medical Devices · Diabetes Care 1,981 1,648 +20.2%
Medical Devices · Electrophysiology 700 627 +11.6%
Medical Devices · Heart Failure 368 321 +14.6%
Medical Devices · Neuromodulation 254 243 +4.5%
Medical Devices · Non Us 2,866 2,549 +12.4%
Medical Devices · Non Us 1,187 1,011 +17.4%
Medical Devices · Non Us 378 340 +11.2%
Medical Devices · Non Us 86 77 +11.7%
Medical Devices · Non Us 61 51 +19.6%
Medical Devices · Non Us 333 315 +5.7%
Medical Devices · Non Us 347 306 +13.4%
Medical Devices · Non Us 474 449 +5.6%
Medical Devices · Operating Segments 5,369 4,734 +13.4%
Medical Devices · Rhythm Management 673 607 +10.9%
Medical Devices · Structural Heart 636 564 +12.8%
Medical Devices · US 2,503 2,185 +14.6%
Medical Devices · US 794 637 +24.6%
Medical Devices · US 322 287 +12.2%
Medical Devices · US 282 244 +15.6%
Medical Devices · US 193 192 +0.5%
Medical Devices · US 340 292 +16.4%
Medical Devices · US 289 258 +12.0%
Medical Devices · US 283 275 +2.9%
Medical Devices · Vascular 757 724 +4.6%
Nutritionals · Adult Nutritionals 1,158 1,091 +6.1%
Nutritionals · Non Us 1,255 1,217 +3.1%
Nutritionals · Non Us 788 722 +9.1%
Nutritionals · Non Us 467 495 -5.7%
Nutritionals · Operating Segments 2,212 2,150 +2.9%
Nutritionals · Pediatric Nutritionals 1,054 1,059 -0.5%
Nutritionals · US 957 933 +2.6%
Nutritionals · US 370 369 +0.3%
Nutritionals · US 587 564 +4.1%
Show Geography breakouts
Non Us 6,866 6,443 +6.6%
US 4,276 3,934 +8.7%
US · Corporate Non Segment 5 4 +25.0%
Show Consolidation Items breakouts
Corporate Non Segment 5 4 +25.0%
Operating Segments 11,137 10,373 +7.4%
Cost of Revenue 4,854 4,603 +5.5%
Show Business Segments breakouts
Diagnostics · Operating Segments 1,224 1,203 +1.7%
Established Pharmaceuticals · Operating Segments 631 591 +6.8%
Medical Devices · Operating Segments 1,758 1,627 +8.1%
Nutritionals · Operating Segments 1,155 1,148 +0.6%
Show Consolidation Items breakouts
Operating Segments 4,768 4,569 +4.4%
Total Costs & Expenses 9,090 8,708 +4.4%
Research & Development 725 698 +3.9%
Show Business Segments breakouts
Diagnostics · Operating Segments 154 162 -4.9%
Established Pharmaceuticals · Operating Segments 43 44 -2.3%
Medical Devices · Operating Segments 430 379 +13.5%
Nutritionals · Operating Segments 54 53 +1.9%
Show Consolidation Items breakouts
Operating Segments 681 638 +6.7%
Selling, General & Administrative 3,091 2,936 +5.3%
Show Business Segments breakouts
Diagnostics · Operating Segments 423 400 +5.8%
Established Pharmaceuticals · Operating Segments 363 344 +5.5%
Medical Devices · Operating Segments 1,385 1,221 +13.4%
Nutritionals · Operating Segments 585 576 +1.6%
Show Consolidation Items breakouts
Operating Segments 2,756 2,541 +8.5%
Operating Income 2,052 1,669 +22.9%
Show Business Segments breakouts
Diagnostics · Operating Segments 372 430 -13.5%
Established Pharmaceuticals · Operating Segments 346 315 +9.8%
Medical Devices · Operating Segments 1,796 1,507 +19.2%
Nutritionals · Operating Segments 418 373 +12.1%
Show Consolidation Items breakouts
Operating Segments 2,932 2,625 +11.7%
Interest Expense 121 140 -13.6%
Interest Income -71 -82 +13.4%
Other Non-Operating Income (Expense) -137 10 -1470.0%
Income Before Taxes 2,150 1,607 +33.8%
Income Tax Expense (Benefit) 371 305 +21.6%
Net Income 1,779 1,302 +36.6%
Show Equity Components breakouts
Retained Earnings 1,779 1,302 +36.6%
Comprehensive Income 2,620 1,333 +96.5%
Other Comprehensive Income 841 31 +2612.9%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 841 31 +2612.9%
EPS (Basic) 1.02 0.74 +37.8%
EPS (Diluted) 1.01 0.74 +36.5%
Wtd Avg Shares (Basic) 1,743,437 1,743,040 0.0%
Wtd Avg Shares (Diluted) 1,750,835 1,751,153 -0.0%
Foreign Currency Transaction Gain Loss Before Tax -11 -6 -83.3%
Net Income Loss Available To Common Stockholders Basic 1.8 1.3 +38.5%

Balance Sheet

Balance Sheet
Metric Q2 2025 Q2 2024 YoY
Current Assets
Cash & Cash Equivalents 6,951 6,987 -0.5%
Short-Term Investments 331 232 +42.7%
Accounts Receivable 7,972 6,854 +16.3%
Inventory 6,954 6,814 +2.1%
Total Current Assets 24,468 23,119 +5.8%
Non-Current Assets
Property, Plant & Equipment 11,395 10,233 +11.4%
Goodwill 23,952 — —
Show Business Segments breakouts
Diagnostics 3.6 — —
Established Pharmaceuticals 2.7 — —
Medical Devices 17.3 — —
Nutritionals 285 — —
Total Assets 83,999 — —
Show Business Segments breakouts
Diagnostics · Operating Segments 8,177 — —
Established Pharmaceuticals · Operating Segments 3,732 — —
Medical Devices · Operating Segments 10,555 — —
Nutritionals · Operating Segments 4,910 — —
Show Consolidation Items breakouts
Operating Segments 27,374 — —
Long Term Investments 958 — —
Show Fair Value By Measurement Basis breakouts
Carrying Reported Amount Fair Value Disclosure · Equity Securities 619 — —
Carrying Reported Amount Fair Value Disclosure · Other Aggregated Investments 339 — —
Estimate Of Fair Value Fair Value Disclosure · Equity Securities 619 — —
Estimate Of Fair Value Fair Value Disclosure · Other Aggregated Investments 339 — —
Show Investment Type breakouts
Equity Securities 619 — —
Other Investments 339 — —
Current Liabilities
Current Portion of Long-Term Debt 507 1,615 -68.6%
Total Current Liabilities 13,439 13,760 -2.3%
Non-Current Liabilities
Long-Term Debt 12,930 13,139 -1.6%
Long-Term Debt (Q) — — —
Show Fair Value By Measurement Basis breakouts
Carrying Reported Amount Fair Value Disclosure -13,437 — —
Estimate Of Fair Value Fair Value Disclosure -13,221 — —
Stockholders' Equity
Common Stock 25,284 24,858 +1.7%
Retained Earnings 48,467 38,354 +26.4%
Accumulated Other Comprehensive Income -6,576 -8,135 +19.2%
Total Stockholders' Equity 50,565 — —
Total Liabilities & Equity 83,999 73,017 +15.0%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q2 2025 YTD Q2 2024 YoY
Operating Activities
Stock-Based Compensation 431 445 -3.1%
Change in Accounts Receivable -672 -476 -41.2%
Change in Inventory -252 -513 +50.9%
Net Cash from Operations 3,464 2,985 +16.0%
Investing Activities
Capital Expenditures -986 -931 -5.9%
Other Investing Activities 8 3 +166.7%
Net Cash from Investing -1,052 -878 -19.8%
Financing Activities
Share Repurchases -286 -229 -24.9%
Net Cash from Financing -3,152 -1,967 -60.2%
Other Cash Flow
Net Change in Cash -665 91 -830.8%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key